TY - JOUR A1 - Cheng, Cheng A1 - MacIntyre, Lynsey A1 - Ramadan Abdelmohsen, Usama A1 - Horn, Hannes A1 - Polymenakou, Paraskevi N. A1 - Edrada-Ebel, RuAngelie A1 - Hentschel, Ute T1 - Biodiversity, Anti-Trypanosomal Activity Screening, and Metabolomic Profiling of Actinomycetes Isolated from Mediterranean Sponges JF - PLoS One N2 - Marine sponge–associated actinomycetes are considered as promising sources for the discovery of novel biologically active compounds. In the present study, a total of 64 actinomycetes were isolated from 12 different marine sponge species that had been collected offshore the islands of Milos and Crete, Greece, eastern Mediterranean. The isolates were affiliated to 23 genera representing 8 different suborders based on nearly full length 16S rRNA gene sequencing. Four putatively novel species belonging to genera Geodermatophilus, Microlunatus, Rhodococcus and Actinomycetospora were identified based on a 16S rRNA gene sequence similarity of < 98.5% to currently described strains. Eight actinomycete isolates showed bioactivities against Trypanosma brucei brucei TC221 with half maximal inhibitory concentration (IC50) values <20 μg/mL. Thirty four isolates from the Milos collection and 12 isolates from the Crete collection were subjected to metabolomic analysis using high resolution LC-MS and NMR for dereplication purposes. Two isolates belonging to the genera Streptomyces (SBT348) and Micromonospora (SBT687) were prioritized based on their distinct chemistry profiles as well as their anti-trypanosomal activities. These findings demonstrated the feasibility and efficacy of utilizing metabolomics tools to prioritize chemically unique strains from microorganism collections and further highlight sponges as rich source for novel and bioactive actinomycetes. KW - streptomyces KW - drug metabolism KW - metabolites KW - ribosomal RNA KW - metabolomics KW - actinobacteria KW - sponges KW - secondary metabolites Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125138 VL - 10 IS - 9 ER - TY - JOUR A1 - Abdelmohsen, Usama Ramadan A1 - Cheng, Cheng A1 - Viegelmann, Christina A1 - Zhang, Tong A1 - Grkovic, Tanja A1 - Ahmed, Safwat A1 - Quinn, Ronald J. A1 - Hentschel, Ute A1 - Edrada-Ebel, RuAngelie T1 - Dereplication Strategies for Targeted Isolation of New Antitrypanosomal Actinosporins A and B from a Marine Sponge Associated-Actinokineospora sp EG49 JF - Marine Drugs N2 - High resolution Fourier transform mass spectrometry (HRFTMS) and nuclear magnetic resonance (NMR) spectroscopy were employed as complementary metabolomic tools to dereplicate the chemical profile of the new and antitrypanosomally active sponge-associated bacterium Actinokineospora sp. EG49 extract. Principal Component (PCA), hierarchical clustering (HCA), and orthogonal partial least square-discriminant analysis (OPLS-DA) were used to evaluate the HRFTMS and NMR data of crude extracts from four different fermentation approaches. Statistical analysis identified the best culture one-strain-many-compounds (OSMAC) condition and extraction procedure, which was used for the isolation of novel bioactive metabolites. As a result, two new O-glycosylated angucyclines, named actinosporins A (1) and B (2), were isolated from the broth culture of Actinokineospora sp. strain EG49, which was cultivated from the Red Sea sponge Spheciospongia vagabunda. The structures of actinosporins A and B were determined by 1D- and 2D-NMR techniques, as well as high resolution tandem mass spectrometry. Testing for antiparasitic properties showed that actinosporin A exhibited activity against Trypanosoma brucei brucei with an IC₅₀ value of 15 µM; however no activity was detected against Leishmania major and Plasmodium falciparum, therefore suggesting its selectivity against the parasite Trypanosoma brucei brucei; the causative agent of sleeping sickness. KW - dereplication KW - secondary metabolomics KW - anti-trypanosoma KW - Actinokineospora KW - Spheciospongia vagabunda KW - actinosporins Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-119876 SN - 1660-3397 VL - 12 IS - 3 ER - TY - THES A1 - Cheng, Cheng T1 - Metabolomics and dereplication-based isolation of novel bioactive natural products from marine sponge-associated actinomycetes T1 - Metabolomik und Dereplikations-basierte Isolierung von neuen bioaktiven Naturstoffen aus marinen, Schwamm-assoziierten Actinomyceten N2 - Marine sponge-associated actinomycetes are considered as promising source for the discovery of novel biologically active compounds. Metabolomics coupled multivariate analysis can efficiently reduce the chemical redundancy of re-isolating known compounds at the very early stage of natural product discovery. This Ph.D. project aimed to isolate biologically active secondary metabolites from actinomycetes associated with different Mediterranean sponges with the assistance of metabolomics tools to implement a rapid dereplication and chemically distinct candidate targeting for further up-scaling compounds isolation. This study first focused on the recovery of actinomycetes from marine sponges by various cultivation efforts. Twelve different media and two separate pre-treatments of each bacterial extract were designed and applied to facilitate actinomycete diversity and richness. A total of 64 actinomycetes were isolated from 12 different marine sponge species. The isolates were affiliated to 23 genera representing 8 different suborders based on nearly full-length 16S rRNA gene sequencing. Four putatively novel species belonging to the genera Geodermatophilus, Microlunatus, Rhodococcus, and Actinomycetospora were identified based on a sequence similarity <98.5% to validly described 16S rRNA gene sequences. 20% of the isolated actinomycetes was shown to exhibit diverse biological properties, including antioxidant, anti-Bacillus sp., anti-Aspergillus sp., and antitrypanosomal activities. The metabolomics approaches combined with the bioassay results identified two candidate strains Streptomyces sp. SBT348 and Streptomyces sp. SBT345 for further up-scaling cultivation and compounds isolation. Four compounds were isolated from Streptomyces sp. SBT348. Three of these compounds including the new cyclic dipeptide petrocidin A were previously highlighted in the metabolomics analyses, corroborating the feasibility of metabolomics approaches in novel compounds discovery. These four compounds were also tested against two pathogen microorganisms since the same activities were shown in their crude extract in the preliminary bioassay screening, however none of them displayed the expected activities, which may ascribe to the insufficient amount obtained. Streptomyces sp. SBT345 yielded 5 secondary metabolites, three of which were identified as new natural products, namely strepthonium A, ageloline A and strepoxazine A. Strepthonium A inhibited the production of Shiga toxin produced by enterohemorrhagic Escherichia coli at a concentration of 80 μM, without interfering with the bacterial growth. Ageloline A exhibited antioxidant activity and inhibited the inclusion of Chlamydia trachomatis with an IC50 value of 9.54 ± 0.36 μM. Strepoxazine A displayed antiproliferative property towards human promyelocytic HL-60 cells with an IC50 value of 16 μg/ml. 11 These results highlighted marine sponges as a rich source for novel actinomycetes and further exhibited the significance of marine sponge-associated actinomycetes as promising producers of novel biologically active compounds. The chemometrics coupled metabolomics approach also demonstrated its feasibility and efficacy in natural product discovery. N2 - Schwamm-assoziierte Actinomyceten stellen eine vielversprechende Quelle für die Entdeckung neuer, biologisch aktiver Verbindungen dar. Metabolomik gekoppelte multivariate Datenalyse kann die erneute Isolation bekannter chemischer Verbindungen in einem frühen Stadium drastisch reduzieren und der Entdeckung neuer Naturstoffe dadurch effizienter machen. Das Ziel dieser Arbeit war es, biologisch aktive Sekundärmetabolite aus Actinomyceten, welche mit Mittelmeerschwämmen assoziiert sind, zu isolieren. Mithilfe von Werkzeugen aus der Metabolomik soll eine schnelle Dereplikation sowie gezielte Auswahl an chemischen Verbindungen implementiert werden um diese nachfolgend und in hohem Durchsatz isolieren zu können. Diese Promotions-Arbeit konzentriert sich zunächst auf die Isolation von Actinomyceten aus marinen Schwämmen mittels verschiedener Kultivierungsmethoden. Zwölf verschiedene Medien sowie zwei unterschiedliche Vorbehandlungen der bakteriellen Extrakte wurden angewendet, um die Kultivierung diverser Actinomyceten zu ermöglichen. Insgesamt konnten damit 64 Actinomyceten aus 12 unterschiedlichen Schwämmen isoliert worden. Mithilfe der Sequenzierung von 16S rRNA Sequenzen konnten diese bakteriellen Isolate 23 Gattungen und 8 Unterordnungen zugewiesen werden. Aufgrund von Sequenzähnlichkeiten <98.5% wurden 4 neue Arten identifiziert, welche zu den folgenden Gattungen gehören: Geodermatophilus, Microlunatus, Rhodococcus and Actinomycetospora. 20% der isolierten Actinomyceten wurde gezeigt, die verschiedene biologische Eigenschaften aufweisen, einschließlich antixocidativer, antibakterieller, Fungiziden Eigenschaften sowie ihrer anti- Trypanosomen -Aktivitäten. Mithilfe metabolomischer Methoden und Bioassays konnten zwei bakterielle Stämme, Streptomyces sp. SBT348 und Streptomyces sp. SBT345, für deren Kultivierung und Isolierung chemischer Verbindung identifiziert werden. Aus dem Stamm Streptomyces sp. SBT348 konnten vier neue Verbindungen isoliert werden, darunter ein neues, zyklisches Dipeptid Petrocidin A. Drei dieser Verbindungen, einschließlich Petrocidin A, wurden bei der Datenanalyse der Metabolomik hervorgehoben. Das bestätigte die Durchführbarkeit metabolomischer Methoden für die Entdeckung neuer Verbindungen. Allerdings zeigte keine Verbindung die erwarteten Aktivitäten. Das könnte darauf zurückgeführt werden, dass die erhaltenen Mengen unzureichend waren. In Streptomyces sp. SBT345 konnten fünf Sekundärmetabolite identifiziert werden, von welchen drei - Strepthonium A, Ageloline A und Strepoxazine A - als neue Naturstoffe identifiziert werden konnten. Durch Strepthonium A in einer Konzentration von 80 µM konnte die Produktion des Shiga-Toxins in Escherichia coli gehemmt werden, ohne dessen bakterielles Wachstum zu beeinflussen. Ageloline A wirkte antioxidativ und hemmte Chlamydia trachomatis mit einem IC50 Wert von 9.54 ± 0.36 µM. Strepoxazine A zeigte eine wachstumshemmende Wirkung gegenüber HL-60 Zellen (humane Promyelozytenleukämie-Zellen) bei einem IC50 Wert von 16 µg/ml. Die Ergebnisse zeigen auf, dass marine Schwämme viele bisher unbekannte Actinomyceten beherbergen. Diesen Actinomyceten ist eine hohe Bedeutung beizumessen, da sie eine vielversprechende Quelle für neue, biologisch aktive Verbindungen darstellen. Es konnte ebenfalls gezeigt werden, dass der methodische Ansatz via chemometrischer und metabolomischer Methoden gut durchführbar und effizient ist und daher für die Entdeckung von Naturstoffen sehr gut geeignet ist. KW - Actinomyces KW - Schwämme KW - Sekundärmetabolit KW - Metabolomik KW - Marine natural products KW - Actinomycetes KW - Metabolomics KW - Marine sponges KW - Natural products KW - Dereplicaiton Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-136587 ER - TY - JOUR A1 - Macintyre, Lynsey A1 - Zhang, Tong A1 - Viegelmann, Christina A1 - Martinez, Ignacio Juarez A1 - Cheng, Cheng A1 - Dowdells, Catherine A1 - Abdelmohsen, Usama Ramadan A1 - Gernert, Christine A1 - Hentschel, Ute A1 - Edrada-Ebel, RuAngelie T1 - Metabolomic Tools for Secondary Metabolite Discovery from Marine Microbial Symbionts JF - Marine Drugs N2 - Marine invertebrate-associated symbiotic bacteria produce a plethora of novel secondary metabolites which may be structurally unique with interesting pharmacological properties. Selection of strains usually relies on literature searching, genetic screening and bioactivity results, often without considering the chemical novelty and abundance of secondary metabolites being produced by the microorganism until the time-consuming bioassay-guided isolation stages. To fast track the selection process, metabolomic tools were used to aid strain selection by investigating differences in the chemical profiles of 77 bacterial extracts isolated from cold water marine invertebrates from Orkney, Scotland using liquid chromatography-high resolution mass spectrometry (LC-HRMS) and nuclear magnetic resonance (NMR) spectroscopy. Following mass spectrometric analysis and dereplication using an Excel macro developed in-house, principal component analysis (PCA) was employed to differentiate the bacterial strains based on their chemical profiles. NMR H-1 and correlation spectroscopy (COSY) were also employed to obtain a chemical fingerprint of each bacterial strain and to confirm the presence of functional groups and spin systems. These results were then combined with taxonomic identification and bioassay screening data to identify three bacterial strains, namely Bacillus sp. 4117, Rhodococcus sp. ZS402 and Vibrio splendidus strain LGP32, to prioritize for scale-up based on their chemically interesting secondary metabolomes, established through dereplication and interesting bioactivities, determined from bioassay screening. KW - multivariate analysis KW - metabolic profiling KW - metabolomics KW - dereplication KW - symbiotic bacteria KW - mass spectrometry KW - NMR KW - sponge holicolona-simulans KW - bryozoan bugula-neritina KW - polyketide synthase gene Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-116097 SN - 1660-3397 VL - 12 IS - 6 ER - TY - JOUR A1 - Cheng, Cheng A1 - Othman, Eman M. A1 - Stopper, Helga A1 - Edrada-Ebel, RuAngelie A1 - Hentschel, Ute A1 - Abdelmohsen, Usama Ramadan T1 - Isolation of petrocidin A, a new cytotoxic cyclic dipeptide from the marine sponge-derived bacterium \(Streptomyces\) sp. SBT348 JF - Marine Drugs N2 - A new cyclic dipeptide, petrocidin A (\(\textbf{1}\)), along with three known compounds—2,3-dihydroxybenzoic acid (\(\textbf{2}\)), 2,3-dihydroxybenzamide (\(\textbf{3}\)), and maltol (\(\textbf{4}\))—were isolated from the solid culture of \(Streptomyces\) sp. SBT348. The strain \(Streptomyces\) sp. SBT348 had been prioritized in a strain collection of 64 sponge-associated actinomycetes based on its distinct metabolomic profile using liquid chromatography/high-resolution mass spectrometry (LC-HRMS) and nuclear magnetic resonance (NMR). The absolute configuration of all α-amino acids was determined by HPLC analysis after derivatization with Marfey’s reagent and comparison with commercially available reference amino acids. Structure elucidation was pursued in the presented study by mass spectrometry and NMR spectral data. Petrocidin A (\(\textbf{1}\)) and 2,3-dihydroxybenzamide (\(\textbf{3}\)) exhibited significant cytotoxicity towards the human promyelocytic HL-60 and the human colon adenocarcinoma HT-29 cell lines. These results demonstrated the potential of sponge-associated actinomycetes for the discovery of novel and pharmacologically active natural products. KW - biology KW - sponges KW - actinomycetes KW - streptomyces KW - cyclic dipeptide KW - cytotoxic Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172644 VL - 15 IS - 12 ER - TY - JOUR A1 - Kreissl, Michael C. A1 - Stout, David B. A1 - Wong, Koon-Pong A1 - Wu, Hsiao-Ming A1 - Caglayan, Evren A1 - Ladno, Waldemar A1 - Zhang, Xiaoli A1 - Prior, John A1 - Reiners, Christoph A1 - Huang, Sung-Cheng A1 - Schelbert, Heinrich R. T1 - Influence of Dietary Interventions and Insulin on Myocardial, Skeletal Muscle and Brain [18F]-Fluorodeoxyglucose Kinetics in Mice N2 - Background: We evaluated the effect of insulin stimulation and dietary changes on myocardial, skeletal muscle and brain [18F]-fluorodeoxyglucose (FDG) kinetics and uptake in vivo in intact mice. Methods: Mice were anesthetized with isoflurane and imaged under different conditions: non-fasted (n = 7; "controls"), non-fasted with insulin (2 IU/kg body weight) injected subcutaneously immediately prior to FDG (n = 6), fasted (n = 5), and fasted with insulin injection (n = 5). A 60-min small-animal PET with serial blood sampling and kinetic modeling was performed. Results: We found comparable FDG standardized uptake values (SUVs) in myocardium in the non-fasted controls and non-fasted-insulin injected group (SUV 45-60 min, 9.58 ± 1.62 vs. 9.98 ± 2.44; p = 0.74), a lower myocardial SUV was noted in the fasted group (3.48 ± 1.73; p < 0.001). In contrast, the FDG uptake rate constant (Ki) for myocardium increased significantly by 47% in non-fasted mice by insulin (13.4 ± 3.9 ml/min/100 g vs. 19.8 ± 3.3 ml/min/100 g; p = 0.030); in fasted mice, a lower myocardial Ki as compared to controls was observed (3.3 ± 1.9 ml/min/100 g; p < 0.001). Skeletal muscle SUVs and Ki values were increased by insulin independent of dietary state, whereas in the brain, those parameters were not influenced by fasting or administration of insulin. Fasting led to a reduction in glucose metabolic rate in the myocardium (19.41 ± 5.39 vs. 3.26 ± 1.97 mg/min/100 g; p < 0.001), the skeletal muscle (1.06 ± 0.34 vs. 0.34 ± 0.08 mg/min/100 g; p = 0.001) but not the brain (3.21 ± 0.53 vs. 2.85 ± 0.25 mg/min/100 g; p = 0.19). Conclusions: Changes in organ SUVs, uptake rate constants and metabolic rates induced by fasting and insulin administration as observed in intact mice by small-animal PET imaging are consistent with those observed in isolated heart/muscle preparations and, more importantly, in vivo studies in larger animals and in humans. When assessing the effect of insulin on the myocardial glucose metabolism of non-fasted mice, it is not sufficient to just calculate the SUV - dynamic imaging with kinetic modeling is necessary. KW - Insulin KW - Gehirn KW - Skelettmuskel KW - Maus Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68775 ER - TY - JOUR A1 - Galluzzi, L. A1 - Bravo-San Pedro, J. M. A1 - Vitale, I. A1 - Aaronson, S. A. A1 - Abrams, J. M. A1 - Adam, D. A1 - Alnemri, E. S. A1 - Altucci, L. A1 - Andrews, D. A1 - Annicchiarico-Petruzelli, M. A1 - Baehrecke, E. H. A1 - Bazan, N. G. A1 - Bertrand, M. J. A1 - Bianchi, K. A1 - Blagosklonny, M. V. A1 - Blomgren, K. A1 - Borner, C. A1 - Bredesen, D. E. A1 - Brenner, C. A1 - Campanella, M. A1 - Candi, E. A1 - Cecconi, F. A1 - Chan, F. K. A1 - Chandel, N. S. A1 - Cheng, E. H. A1 - Chipuk, J. E. A1 - Cidlowski, J. A. A1 - Ciechanover, A. A1 - Dawson, T. M. A1 - Dawson, V. L. A1 - De Laurenzi, V. A1 - De Maria, R. A1 - Debatin, K. M. A1 - Di Daniele, N. A1 - Dixit, V. M. A1 - Dynlacht, B. D. A1 - El-Deiry, W. S. A1 - Fimia, G. M. A1 - Flavell, R. A. A1 - Fulda, S. A1 - Garrido, C. A1 - Gougeon, M. L. A1 - Green, D. R. A1 - Gronemeyer, H. A1 - Hajnoczky, G. A1 - Hardwick, J. M. A1 - Hengartner, M. O. A1 - Ichijo, H. A1 - Joseph, B. A1 - Jost, P. J. A1 - Kaufmann, T. A1 - Kepp, O. A1 - Klionsky, D. J. A1 - Knight, R. A. A1 - Kumar, S. A1 - Lemasters, J. J. A1 - Levine, B. A1 - Linkermann, A. A1 - Lipton, S. A. A1 - Lockshin, R. A. A1 - López-Otín, C. A1 - Lugli, E. A1 - Madeo, F. A1 - Malorni, W. A1 - Marine, J. C. A1 - Martin, S. J. A1 - Martinou, J. C. A1 - Medema, J. P. A1 - Meier, P. A1 - Melino, S. A1 - Mizushima, N. A1 - Moll, U. A1 - Muñoz-Pinedo, C. A1 - Nuñez, G. A1 - Oberst, A. A1 - Panaretakis, T. A1 - Penninger, J. M. A1 - Peter, M. E. A1 - Piacentini, M. A1 - Pinton, P. A1 - Prehn, J. H. A1 - Puthalakath, H. A1 - Rabinovich, G. A. A1 - Ravichandran, K. S. A1 - Rizzuto, R. A1 - Rodrigues, C. M. A1 - Rubinsztein, D. C. A1 - Rudel, T. A1 - Shi, Y. A1 - Simon, H. U. A1 - Stockwell, B. R. A1 - Szabadkai, G. A1 - Tait, S. W. A1 - Tang, H. L. A1 - Tavernarakis, N. A1 - Tsujimoto, Y. A1 - Vanden Berghe, T. A1 - Vandenabeele, P. A1 - Villunger, A. A1 - Wagner, E. F. A1 - Walczak, H. A1 - White, E. A1 - Wood, W. G. A1 - Yuan, J. A1 - Zakeri, Z. A1 - Zhivotovsky, B. A1 - Melino, G. A1 - Kroemer, G. T1 - Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 JF - Cell Death and Differentiation N2 - Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally referred to as 'accidental cell death' (ACD). In most settings, however, cell death is initiated by a genetically encoded apparatus, correlating with the fact that its course can be altered by pharmacologic or genetic interventions. 'Regulated cell death' (RCD) can occur as part of physiologic programs or can be activated once adaptive responses to perturbations of the extracellular or intracellular microenvironment fail. The biochemical phenomena that accompany RCD may be harnessed to classify it into a few subtypes, which often (but not always) exhibit stereotyped morphologic features. Nonetheless, efficiently inhibiting the processes that are commonly thought to cause RCD, such as the activation of executioner caspases in the course of apoptosis, does not exert true cytoprotective effects in the mammalian system, but simply alters the kinetics of cellular demise as it shifts its morphologic and biochemical correlates. Conversely, bona fide cytoprotection can be achieved by inhibiting the transduction of lethal signals in the early phases of the process, when adaptive responses are still operational. Thus, the mechanisms that truly execute RCD may be less understood, less inhibitable and perhaps more homogeneous than previously thought. Here, the Nomenclature Committee on Cell Death formulates a set of recommendations to help scientists and researchers to discriminate between essential and accessory aspects of cell death. Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121207 VL - 22 ER - TY - JOUR A1 - Manchia, Mirko A1 - Adli, Mazda A1 - Akula, Nirmala A1 - Arda, Raffaella A1 - Aubry, Jean-Michel A1 - Backlund, Lena A1 - Banzato, Claudio E. M. A1 - Baune, Bernhard T. A1 - Bellivier, Frank A1 - Bengesser, Susanne A1 - Biernacka, Joanna M. A1 - Brichant-Petitjean, Clara A1 - Bui, Elise A1 - Calkin, Cynthia V. A1 - Cheng, Andrew Tai Ann A1 - Chillotti, Caterina A1 - Cichon, Sven A1 - Clark, Scott A1 - Czerski, Piotr M. A1 - Dantas, Clarissa A1 - Del Zompo, Maria A1 - DePaulo, J. Raymond A1 - Detera-Wadleigh, Sevilla D. A1 - Etain, Bruno A1 - Falkai, Peter A1 - Frisén, Louise A1 - Frye, Mark A. A1 - Fullerton, Jan A1 - Gard, Sébastien A1 - Garnham, Julie A1 - Goes, Fernando S. A1 - Grof, Paul A1 - Gruber, Oliver A1 - Hashimoto, Ryota A1 - Hauser, Joanna A1 - Heilbronner, Urs A1 - Hoban, Rebecca A1 - Hou, Liping A1 - Jamain, Stéphane A1 - Kahn, Jean-Pierre A1 - Kassem, Layla A1 - Kato, Tadafumi A1 - Kelsoe, John R. A1 - Kittel-Schneider, Sarah A1 - Kliwicki, Sebastian A1 - Kuo, Po-Hsiu A1 - Kusumi, Ichiro A1 - Laje, Gonzalo A1 - Lavebratt, Catharina A1 - Leboyer, Marion A1 - Leckband, Susan G. A1 - López Jaramillo, Carlos A. A1 - Maj, Mario A1 - Malafosse, Alain A1 - Martinsson, Lina A1 - Masui, Takuya A1 - Mitchell, Philip B. A1 - Mondimore, Frank A1 - Monteleone, Palmiero A1 - Nallet, Audrey A1 - Neuner, Maria A1 - Novák, Tomás A1 - O'Donovan, Claire A1 - Ösby, Urban A1 - Ozaki, Norio A1 - Perlis, Roy H. A1 - Pfennig, Andrea A1 - Potash, James B. A1 - Reich-Erkelenz, Daniela A1 - Reif, Andreas A1 - Reininghaus, Eva A1 - Richardson, Sara A1 - Rouleau, Guy A. A1 - Rybakowski, Janusz K. A1 - Schalling, Martin A1 - Schofield, Peter R. A1 - Schubert, Oliver K. A1 - Schweizer, Barbara A1 - Seemüller, Florian A1 - Grigoroiu-Serbanescu, Maria A1 - Severino, Giovanni A1 - Seymour, Lisa R. A1 - Slaney, Claire A1 - Smoller, Jordan W. A1 - Squassina, Alessio A1 - Stamm, Thomas A1 - Steele, Jo A1 - Stopkova, Pavla A1 - Tighe, Sarah K. A1 - Tortorella, Alfonso A1 - Turecki, Gustavo A1 - Wray, Naomi R. A1 - Wright, Adam A1 - Zandi, Peter P. A1 - Zilles, David A1 - Bauer, Michael A1 - Rietschel, Marcella A1 - McMahon, Francis J. A1 - Schulze, Thomas G. A1 - Alda, Martin T1 - Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report JF - PLoS ONE N2 - Objective: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study. Materials and Methods: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (\(\kappa\))] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling. Results: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (\(\kappa\) = 0.66 and \(\kappa\) = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (\(ICC_1 = 0.71\) and \(ICC_2 = 0.75\), respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders). Conclusions: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study. KW - age KW - observer agreement KW - prophylactic lithium KW - mapping susceptibility genes KW - mood disorders KW - onset KW - association KW - reliability KW - morality KW - illness Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130938 VL - 8 IS - 6 ER - TY - JOUR A1 - Rose, Kathleen M. A1 - Szopa, Jan A1 - Han, Fu-Sheng A1 - Cheng, Yung-Chi A1 - Richter, Arndt A1 - Scheer, Ulrich T1 - Association of DNA topoisomerase I and RNA polymerase I: A possible role for topoisomerase I in ribosomal gene transcription N2 - RNA polymerase I preparations purified from a rat hepatoma contained DNA topoisomerase activity. The DNA topoisomerase associated with the polymerase had an Mr of 110000, required Mg2+ but not ATP, and was recognized by anti-topoisomerase I antibodies. When added to RNA polymerase I preparations containing topoisomerase activity, anti-topoisomerase I antibodies were able to inhibit the DNA relaxing activity of the preparation as well as RNA synthesis in vitro. RNA polymerase II prepared by analogous procedures did not contain topoisomerase activity and was not recognized by the antibodies. The topoisomerase I: polymerase I complex was reversibly dissociated by column chromatography on Sephacryl S200 in the presence of 0.25 M (NH4hS04. Topoisomerase I was immunolocalized in the transcriptionally active ribosomal gene complex containing RNA polymerase I in situ. These data indicate that topoisomerase I and RNA polymerase I are tightly complexed both in vivo and in vitro, and suggest a role for DNA topoisomerase I in the transcription of ribosomal genes. Y1 - 1988 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-33901 ER - TY - THES A1 - Zhu, Ana Cheng T1 - Metagenomic analysis of genetic variation in human gut microbial species T1 - Metagenomische Analysen der genetischen Variationen in menschlichen Darmbakterien N2 - Microbial species (bacteria and archaea) in the gut are important for human health in various ways. Not only does the species composition vary considerably within the human population, but each individual also appears to have its own strains of a given species. While it is known from studies of bacterial pan-genomes, that genetic variation between strains can differ considerably, such as in Escherichia coli, the extent of genetic variation of strains for abundant gut species has not been surveyed in a natural habitat. This is mainly due to the fact that most of these species cannot be cultured in the laboratory. Genetic variation can range from microscale genomic rearrangements such as small nucleotide polymorphism (SNP) to macroscale large genomic rearrangements like structural variations. Metagenomics offers an alternative solution to study genetic variation in prokaryotes, as it involves DNA sequencing of the whole community directly from the environment. However, most metagenomic studies to date only focus on variation in gene abundance and hence are not able to characterize genetic variation (in terms of presence or absence of SNPs and genes) of gut microbial strains of individuals. The aim of my doctorate studies was therefore to study the extent of genetic variation in the genomic sequence of gut prokaryotic species and its phenotypic effects based on: (1) the impact of SNP variation in gut bacterial species, by focusing on genes under selective pressure and (2) the gene content variation (as a proxy for structural variation) and their effect on microbial species and the phenotypic traits of their human host. In the first part of my doctorate studies, I was involved in a project in which we created a catalogue of 10.3 million SNPs in gut prokaryotic species, based on metagenomes. I used this to perform the first SNP-based comparative study of prokaryotic species evolution in a natural habitat. Here, I found that strains of gut microbial species in different individuals evolve at more similar rates than the strains within an individual. In addition, I found that gene evolution can be uncoupled from the evolution of its originating species, and that this could be related to selective pressure such as diet, exemplified by galactokinase gene (galK). Despite the individuality (i.e. uniqueness of each individual within the studied metagenomic dataset) in the SNP profile of the gut microbiota that we found, for most cases it is not possible to link SNPs with phenotypic differences. For this reason I also used gene content as a proxy to study structural variation in metagenomes. In the second part of my doctorate studies, I developed a methodology to characterize the variability of gene content in gut bacterial species, using metagenomes. My approach is based on gene deletions, and was applied to abundant species (demonstrated using a set of 11 species). The method is sufficiently robust as it captures a similar range of gene content variability as has been detected in completely sequenced genomes. Using this procedure I found individuals differ by an average of 13% in their gene content of gut bacterial strains within the same species. Interestingly no two individuals shared the same gene content across bacterial species. However, this variation corresponds to a lower limit, as it is only accounts for gene deletion and not insertions. This large variation in the gene content of gut strain was found to affect important functions, such as polysaccharide utilization loci (PULs) and capsular polysaccharide synthesis (CPS), which are related with digestion of dietary fibers. In summary, I have shown that metagenomics based approaches can be robust in characterizing genetic variation in gut bacterial species. I also illustrated, using examples both for SNPs and gene content (galK, PULs and CPS), that this genetic variation can be used to predict the phenotypic characteristics of the microbial species, as well as predicting the phenotype of their human host (for example, their capacity to digest different food components). Overall, the results of my thesis highlight the importance of characterizing the strains in the gut microbiome analogous to the emerging variability and importance of human genomics. N2 - Mikrobielle Arten (Bakterien und Archaeen) im menschlichen Darm sind wichtige Begleiter für unsere Gesundheit. Jedoch gibt es nicht nur starke Unterschiede zwischen individuellen Wirten in der Artenzusammensetzung des Darmmikrobioms, sondern es scheint sogar Individuen-spezifische Bakterienstämme zu geben. Analysen von Bakterien wie z.B. Escherichia coli haben schon früh gezeigt, dass die Genome von Bakterienstämmen derselben Art große Unterschiede aufzeigen können; jedoch wurden diese Unterschiede bisher noch nicht in einer natürlichen Umgebung gezeigt. Genetische Variation kann viele Ausprägungen haben und reicht von kleinen Veränderungen wie „small nucleotide polymorphism“ (SNP) zu makroskopischen Veränderung, wie z.B. chromosomalen Restrukturierungen. All diese genetischen Variationen wurden bis jetzt nicht in der natürlichen Umgebung der Bakterien studiert, vorallem bedingt durch fehlende Methoden um die meisten dieser Bakterien um Labor zu kultivieren. Metagenomische Studien können hier helfen, da sie unabhängig von Kultivierungen jegliche DNS aus einer natürlichen Bakteriengemeinschaft untersuchen. Jedoch wurde dies in den meisten bisher veröffentlichten metagenomischen Studien nicht ausgenutzt da diese hauptsächlich auf die Anzahl der gefunden Gene ausgerichtet waren. Das Ziel meiner Doktorarbeit war es, die genetische Variation in Darmbakterien zu beschreiben und phenotypische Veränderungen zu untersuchen. Dies habe ich umgesetzt durch die Erforschung (1) der SNP-Varianz in Darmbakterien, mit besonderem Augenmerk auf Gene, die unter einem selektivem Druck stehen und (2) der Variationen in der Genzusammensetzung eines Genomes (als eine Annäherung an strukturelle Variationen) und welchen Effekt dies auf Mikrobenarten und Wirtsphenotypen hat. Im ersten Kapitel meiner Doktorarbeit beschreibe ich meine Arbeit in einem Projekt unserer Gruppe, in dem wir basierend auf metagenomischen Daten 10 Millionen SNPs in menschlichen Darmbakterien beschrieben haben. Diesen Datensatz habe ich verwendet um die erste SNP-basierte, vergleichende Studie der Bakterienevolution in einem natürlichen Habitat zu realisieren. Ich entdeckte, dass Bakterienstämme unabhängig vom Wirt ähnliche evolutionäre Raten haben. Genauer gesagt, die evolutionäre Rate für eine Art ist stabiler zwischen Wirten, als die von verschiedenen Spezies innerhalb eines Wirtes. Ausserdem fand ich heraus, dass die Evolution von einzelnen Genen unabhängig vom restlichen Genom einer Spezies ist. Dies könnte durch einen Selektionsdruck wie z.B. die Ernährung des Wirtes ausgelöst werden, was ich am Beispiel des Galactokinasegenes (galK) gezeigt habe. Obwohl wir zeigen konnten, dass das SNP-Profil der Darmbakterien spezifisch für den jeweiligen Wirt ist, konnten wir keine Assoziation zwischen SNPs und Wirtsphänotypen finden. Auch aus diesem Grund habe ich mich in meiner weiteren Arbeit verstärkt auf makroskopische Genomvariationen konzentriert. Im zweiten Teil meiner Doktoarbeit entwickelte ich eine neue Methode, um Variationen in der genomische Zusammensetzung von einzelnen Bakterienarten zu beschreiben, wieder basierend auf metagenomischen Daten. Hierbei fokussiere ich mich insbesondere auf Gene, die in unseren metagenomischen Daten im Verglich zum Referengenom fehlen und wende dies auf die 11 dominantesten Bakterienspezies an. Diese neue Methode ist robust, da die gefundene Genomvarianz in unseren metagenomischen Daten übereinstimmt mit Daten aus komplett sequenzierten Genomen. So konnte ich herausfinden, dass im Durchschnitt 13% der Gene einer Bakterienart zwischen einzelen Wirten varieren. Besonders interessant ist hier, dass wir keine zwei Wirte gefunden haben, die für eine Bakterienart genau diesselben Gene haben. Jedoch ist die erwarte Varianz aller Wahrscheinlichkeit nach noch größer, da ich mit dieser Methode nur fehlende Gene beschreiben kann, aber nicht neu hinzugekommende. Diese Varianz kann auch wichtige bakterielle Funktionen betreffen, z.B. Gene für „polysaccharide utilization loci“ (PULs) und „capsular polysaccharide synthesis“ (CPS), welche wichtig sind um Ballaststoffe in der Nahrung zu verwerten. Zusammenfassend konnte ich in dieser Arbeit zeigen, dass metagenomische Methoden robust genug sind um die genetische Varianz von Darmbakterien zu beschreiben. Ausserdem konnte ich zeigen, dass die beschriebene Varianz benutzt werden kann, um phenotypische Veränderungen von Bakterien vorherzusagen (demonstriert für die galK, PULs and CPS-Gene). Dies wiederrum könnte benutzt werden um Vorhersagen für den Wirt über z.B. seine Ernährung zu machen. Meine Doktorarbeit zeigt wie wichtig es ist, einzelne Bakterienstämme zu charakterisieren, ganz analog zu der Bedeutsamkeit der genetischen Varianz des menschlichen Genomes. KW - metagenomic KW - Darmflora KW - Metagenom Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-113890 ER -